Survodutide
Metabolic Health · GLP-1/glucagon agonist (dual)
Tier B
Bottom line
Read Off Label grades Survodutide as B (6.8/10) based on strong evidence, high benefit magnitude, and a med-risk safety profile.
Boehringer Ingelheim/Zealand Pharma.
Typical use: 3. — Investigational.
What this is
Boehringer Ingelheim/Zealand Pharma. SYNCHRONIZE-1 (no T2D) Phase 3 topline reported 2026: -16.6% mean body weight at 76 weeks vs -3.2% placebo; full results to be presented at ADA 2026 Scientific Sessions. SYNCHRONIZE-2 (with T2D, n=752) ongoing — both 76-week trials with primary endpoint % body weight change. Phase 2 (Le Roux 2024 Lancet) showed up to 19% weight loss. Particular promise for metabolic-associated steatotic liver disease (MASLD/NAFLD) due to glucagon's hepatic fat oxidation effects. SYNCHRONIZE-1 Phase 3 topline (Apr 2026): up to 16.6% weight loss at 76 weeks vs 3.2% placebo (efficacy estimand), 85% achieving >=5% loss; full data at ADA June 2026. Loss driven predominantly by fat mass.
Mechanism
Dual GLP-1 receptor and glucagon receptor agonist; glucagon arm increases energy expenditure and hepatic fat oxidation; particular interest for MASLD/metabolic liver disease
Dose & route
3.6 or 6.0 mg SC weekly (Phase 3 doses); titrated
Citations
- https://doi.org/10.1111/dom.70196
- https://doi.org/10.1111/dom.70263
- https://doi.org/10.1016/j.conctc.2026.101611
- https://doi.org/10.1186/s12933-026-03140-0
- https://doi.org/10.1007/s11695-026-08692-4
- https://doi.org/10.3390/livers6030035
Links go to the source. If a link is dead or you want something re-checked, let me know.
Common questions
- Does Survodutide work?
- Read Off Label rates the evidence for Survodutide as Strong and the benefit magnitude as high, producing an overall grade of B (6.8/10). Boehringer Ingelheim/Zealand Pharma.
- Is Survodutide safe?
- Survodutide has a med risk profile in published human data. Legal status: Investigational (Phase 3). This is not medical advice — see the disclaimer.
- What is the typical dose for Survodutide?
- 3.6 or 6.0 mg SC weekly (Phase 3 doses); titrated
- How does Survodutide work?
- Dual GLP-1 receptor and glucagon receptor agonist; glucagon arm increases energy expenditure and hepatic fat oxidation; particular interest for MASLD/metabolic liver disease
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.